213 related articles for article (PubMed ID: 15883202)
1. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
2. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Kwok JC; Richardson DR
Mol Pharmacol; 2004 Jan; 65(1):181-95. PubMed ID: 14722250
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
4. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
6. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
8. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
9. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
10. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity.
Kwok JC; Richardson DR
Mol Pharmacol; 2002 Oct; 62(4):888-900. PubMed ID: 12237336
[TBL] [Abstract][Full Text] [Related]
11. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
12. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
14. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Kwok JC; Richardson DR
Mol Pharmacol; 2003 Apr; 63(4):849-61. PubMed ID: 12644586
[TBL] [Abstract][Full Text] [Related]
15. Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide.
Mikhael M; Kim SF; Schranzhofer M; Soe-Lin S; Sheftel AD; Mullner EW; Ponka P
FEBS J; 2006 Aug; 273(16):3828-36. PubMed ID: 16911529
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
[TBL] [Abstract][Full Text] [Related]
18. Interaction of anthracyclines with iron responsive element mRNAs.
Canzoneri JC; Oyelere AK
Nucleic Acids Res; 2008 Dec; 36(21):6825-34. PubMed ID: 18953029
[TBL] [Abstract][Full Text] [Related]
19. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]